Seqens Seqens

X

Find Radio Compass News for Afamelanotide

PharmaCompass
Related ProductsRelated Products
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

SERVICES

0

https://www.globenewswire.com/news-release/2022/05/04/2435187/0/en/Positive-final-results-in-stroke.html

GLOBENEWSWIRE
03 May 2022

https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-27-2022-1651037135.pdf

FDA
27 Apr 2022

https://kalkinemedia.com/au/news/stock-market/clinuvel-enrolls-in-a-world-first-study-of-stroke

KALKINEMEDIA
18 Jan 2022

https://www.globenewswire.com/news-release/2021/11/08/2328862/0/en/CLINUVEL-Expands-Pharmaceutical-Portfolio.html

GLOBENEWSWIRE
07 Nov 2021

https://www.clinuvel.com/first-stroke-patient-treated-with-afamelanotide/

PRESS RELEASE
07 Jun 2021

https://www.biospectrumasia.com/news/25/16291/clinuvel-launches-second-afamelanotide-formulation.html

BIOSPECTRUMASIA
14 Jul 2020

https://www.thepharmaletter.com/in-brief/brief-clinuvel-completes-nda-submission-for-rare-genetic-blood-disorder-drug

THEPHARMALETTER
27 Jun 2018

http://www.pharmatimes.com/news/nice_turns_down_rare_skin_disease_implant_1214791

Selina McKee PHARMA TIMES
20 Dec 2017
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY